Modus Therapeutics participates in Småbolagspodden
Stockholm, Wednesday, October 27, 2021. Modus Therapeutics Holding AB ("Modus") announces that the company participates in the latest episode of Småbolagspodden.Modus’ CEO John Öhd and CFO Claes Lindblad are interviewed by Småbolagspodden's Jonathan Furelid. Listen in to the discussions on sepsis, one of the most prevalent death causes globally and Modus' development of sevuparin for sepsis and other patients with high unmet medical needs, as well as a further look into what the future plans for Modus look like. To listen to the episode via Småbolagspodden, click here